Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03725059




Registration number
NCT03725059
Ethics application status
Date submitted
29/10/2018
Date registered
30/10/2018
Date last updated
18/12/2023

Titles & IDs
Public title
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Scientific title
A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)
Secondary ID [1] 0 0
MK-3475-756
Secondary ID [2] 0 0
3475-756
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Pembrolizumab (K)
Treatment: Drugs - Placebo (P)
Treatment: Drugs - Paclitaxel (X)
Treatment: Drugs - Doxorubicin (A)
Treatment: Drugs - Epirubicin (E)
Treatment: Drugs - Cyclophosphamide (C)
Treatment: Drugs - Endocrine therapy
Treatment: Other - Radiation therapy
Treatment: Surgery - Surgery

Experimental: Pembrolizumab+Chemotherapy (KX/KA[E]C) - In the neoadjuvant setting, participants receive pembrolizumab (K) 200 mg via intravenous (IV) infusion once every 3 weeks (Q3W) + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by pembrolizumab 200 mg via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive pembrolizumab 200 mg via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.

Placebo Comparator: Placebo+Chemotherapy (PX/PA[E]C) - In the neoadjuvant setting, participants receive placebo (P; normal saline or dextrose) via IV infusion Q3W + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by placebo via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive placebo via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.


Other interventions: Pembrolizumab (K)
IV infusion Q3W

Treatment: Drugs: Placebo (P)
Normal saline or dextrose IV infusion Q3W

Treatment: Drugs: Paclitaxel (X)
IV infusion QW

Treatment: Drugs: Doxorubicin (A)
IV infusion either in Q2W or Q3W

Treatment: Drugs: Epirubicin (E)
IV infusion either in Q2W or Q3W

Treatment: Drugs: Cyclophosphamide (C)
IV infusion either in Q2W or Q3W

Treatment: Drugs: Endocrine therapy
Variable endocrine therapy for up 10 years

Treatment: Other: Radiation therapy
Variable radiation therapy per local standard of care

Treatment: Surgery: Surgery
Surgery for breast cancer
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Intervention code [3] 0 0
Treatment: Other
Intervention code [4] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Timepoint [1] 0 0
Up to approximately 7 months (Time of surgery)
Primary outcome [2] 0 0
Event-Free Survival (EFS)
Timepoint [2] 0 0
Up to approximately 12 years
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to approximately 12 years
Secondary outcome [2] 0 0
pCR Rate Using the Definition of ypT0ypN0
Timepoint [2] 0 0
Up to approximately 7 months (Time of surgery)
Secondary outcome [3] 0 0
pCR Rate Using the Definition of ypT0/Tis
Timepoint [3] 0 0
Up to approximately 7 months (Time of surgery)
Secondary outcome [4] 0 0
pCR Rate Using the Definitions of ypT0/Tis ypN0, ypT0/Tis, and ypT0 ypN0 in Participants With a Combined Positive Score [CPS] =1
Timepoint [4] 0 0
Up to approximately 7 months (Time of surgery)
Secondary outcome [5] 0 0
EFS in Participants With a CPS =1
Timepoint [5] 0 0
Up to approximately 12 years
Secondary outcome [6] 0 0
OS in Participants With a CPS =1
Timepoint [6] 0 0
Up to approximately 12 years
Secondary outcome [7] 0 0
Number of Participants Experiencing an Adverse Event (AE)
Timepoint [7] 0 0
Up to approximately 15 months
Secondary outcome [8] 0 0
Number of Participants Experiencing a Serious Adverse Event (SAE)
Timepoint [8] 0 0
Up to approximately 17 months
Secondary outcome [9] 0 0
Number of Participants Experiencing an Immune-related AE (irAE)
Timepoint [9] 0 0
Up to approximately 15 months
Secondary outcome [10] 0 0
Number of Participants who Discontinued Study Treatment Due to an AE
Timepoint [10] 0 0
Up to approximately 14 months
Secondary outcome [11] 0 0
Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire Core 30 (QLQ-C30) Score
Timepoint [11] 0 0
Baseline (Cycle 1 Day 1 in Treatment 1) and Cycles 1 and 4 Day 1 in Treatment 2 (Up to approximately 5 months) Each cycle is 21 days.
Secondary outcome [12] 0 0
Change from Baseline in EORTC Breast Cancer-Specific QoL Questionnaire (QLQ-BR23) Score
Timepoint [12] 0 0
Baseline (Cycle 1 Day 1 in Treatment 1) and Cycles 1 and 4 Day 1 in Treatment 2 (Up to approximately 5 months) Each cycle is 21 days.

Eligibility
Key inclusion criteria
- Has a localized invasive breast ductal adenocarcinoma, confirmed by the local
pathologist, that includes either T1c-T2 (tumor size =2 cm), clinical node stage
(cN)1-cN2, or T3-T4, cN0-cN2. Note: Inflammatory breast cancer is allowed.

- Has centrally confirmed ER+/HER2-, Grade 3 breast cancer of ductal histology,
according to the most recent American Society of Clinical Oncology/College of American
Pathologist guidelines.

- Provides a new or recently obtained core needle biopsy, consisting of multiple cores,
taken from the primary breast tumor(s) for central determination of HR status (ER and
progesterone receptor), HER2, grade, and PD-L1 status.

Note: Sponsor agreement is required for formalin-fixed paraffin-embedded (FFPE) tumor
tissue sample or slides that were obtained greater than 60 days prior to the date that the
documented informed consent was obtained.

- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as
assessed within 10 days prior to initiation of study treatment.

- Male participants must agree to use contraception during the treatment period and for
at least 12 months (for participants who received cyclophosphamide) or 6 months (for
participants who did not receive cyclophosphamide) after the last dose of study
treatment and refrain from donating sperm during this period.

- Female participants must agree to use effective contraception during the treatment
period and for at least 12 months (for participants who received cyclophosphamide) or
6 months (for participants who did not receive cyclophosphamide) after the last dose
of study treatment with pembrolizumab or placebo.

- Has adequate organ function.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has a history of non-infectious pneumonitis that required treatment with steroids or
has current pneumonitis.

- Has breast cancer with lobular histology.

- Has bilateral invasive breast cancer.

- Has metastatic (Stage IV) breast cancer.

- Has multi-centric breast cancer (presence of more than 1 tumor in different quadrants
of the breast).

- Has any of the following clinical lymph node staging per current American Joint
Committee on Cancer (AJCC) staging criteria for breast cancer staging based on
radiological and/or clinical assessment: cN3, cN3a, cN3b, or cN3c.

- Has ER-, progesterone receptor positive breast cancer.

- Has undergone excisional biopsy of the primary tumor and/or axillary lymph nodes or
has undergone sentinel lymph node biopsy prior to study treatment.

- Has a known additional, invasive, malignancy that is progressing or required active
treatment in the last 5 years.

Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the
skin, ductal breast carcinoma in situ, or cervical carcinoma in situ that has undergone
potentially curative therapy are not excluded.

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study treatment.

- Has an active autoimmune disease that has required systemic treatment in the past 2
years (i.e., with use of disease modifying agents, corticosteroids, or
immunosuppressive drugs) Note: Replacement therapy (e.g. thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)
is not considered a form of systemic treatment.

- Has a known history of active tuberculosis (Bacillus tuberculosis).

- Has an active infection requiring systemic therapy.

- Has left ventricular ejection fraction (LVEF) of <50% or below the institution limit
of normal, as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
performed at screening.

- Has other significant cardiac disease, such as: 1) History of myocardial infarction,
acute coronary syndrome, or coronary angioplasty/stenting/bypass within the last 6
months. or 2) Congestive heart failure (CHF) New York Heart Association (NYHA) Class
II-IV or history of CHF NYHA Class III or IV.

- Has a known history of human immunodeficiency virus (HIV) infection.

- Has a known history of hepatitis B or known active hepatitis C virus infection.

- Has received prior treatment for breast cancer.

- Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1),
anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent
directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic
T-lymphocyte-associated protein 4 [CTLA-4], OX 40, CD137).

- Has received a live vaccine within 30 days prior to the first dose of study treatment.

- Has severe hypersensitivity (=Grade 3) to any of the components or excipients used in
the study treatments.

- Is/was enrolled in a study of an investigational agent and received study therapy, or
used an investigational device within 4 weeks (12 months for an investigational agent
or device with anticancer or antiproliferative properties) prior to the first dose of
study treatment.

- Is pregnant, breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 12 months
(for participants who received cyclophosphamide) or 6 months (for participants who did
not receive cyclophosphamide) after the last dose of study treatment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/12/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
24/01/2031
Actual
Sample size
Target
1240
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Chris OBrien Lifehouse ( Site 2107) - Camperdown
Recruitment hospital [2] 0 0
Royal North Shore Hospital ( Site 2100) - Sydney
Recruitment hospital [3] 0 0
Westmead Hospital ( Site 2101) - Sydney
Recruitment hospital [4] 0 0
Mater Misericordiae Ltd ( Site 2106) - South Brisbane
Recruitment hospital [5] 0 0
Frankston Hospital ( Site 2103) - Frankston
Recruitment hospital [6] 0 0
Peter MacCallum Cancer Centre ( Site 2102) - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2065 - Sydney
Recruitment postcode(s) [3] 0 0
2145 - Sydney
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
3199 - Frankston
Recruitment postcode(s) [6] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Montana
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Belgium
State/province [27] 0 0
Antwerpen
Country [28] 0 0
Belgium
State/province [28] 0 0
Bruxelles-Capitale, Region De
Country [29] 0 0
Belgium
State/province [29] 0 0
Liege
Country [30] 0 0
Belgium
State/province [30] 0 0
Limburg
Country [31] 0 0
Belgium
State/province [31] 0 0
Namur
Country [32] 0 0
Belgium
State/province [32] 0 0
Oost-Vlaanderen
Country [33] 0 0
Belgium
State/province [33] 0 0
Vlaams-Brabant
Country [34] 0 0
Belgium
State/province [34] 0 0
West-Vlaanderen
Country [35] 0 0
Brazil
State/province [35] 0 0
Goias
Country [36] 0 0
Brazil
State/province [36] 0 0
Rio Grande Do Sul
Country [37] 0 0
Brazil
State/province [37] 0 0
Santa Catarina
Country [38] 0 0
Brazil
State/province [38] 0 0
Sao Paulo
Country [39] 0 0
Brazil
State/province [39] 0 0
Rio de Janeiro
Country [40] 0 0
Canada
State/province [40] 0 0
Alberta
Country [41] 0 0
Canada
State/province [41] 0 0
British Columbia
Country [42] 0 0
Canada
State/province [42] 0 0
Ontario
Country [43] 0 0
Canada
State/province [43] 0 0
Quebec
Country [44] 0 0
China
State/province [44] 0 0
Anhui
Country [45] 0 0
China
State/province [45] 0 0
Beijing
Country [46] 0 0
China
State/province [46] 0 0
Fujian
Country [47] 0 0
China
State/province [47] 0 0
Guangdong
Country [48] 0 0
China
State/province [48] 0 0
Hebei
Country [49] 0 0
China
State/province [49] 0 0
Heilongjiang
Country [50] 0 0
China
State/province [50] 0 0
Henan
Country [51] 0 0
China
State/province [51] 0 0
Hubei
Country [52] 0 0
China
State/province [52] 0 0
Hunan
Country [53] 0 0
China
State/province [53] 0 0
Jiangsu
Country [54] 0 0
China
State/province [54] 0 0
Jilin
Country [55] 0 0
China
State/province [55] 0 0
Shanghai
Country [56] 0 0
China
State/province [56] 0 0
Shanxi
Country [57] 0 0
China
State/province [57] 0 0
Tianjin
Country [58] 0 0
China
State/province [58] 0 0
Xinjiang
Country [59] 0 0
China
State/province [59] 0 0
Zhejiang
Country [60] 0 0
Colombia
State/province [60] 0 0
Antioquia
Country [61] 0 0
Colombia
State/province [61] 0 0
Atlantico
Country [62] 0 0
Colombia
State/province [62] 0 0
Cordoba
Country [63] 0 0
Colombia
State/province [63] 0 0
Distrito Capital De Bogota
Country [64] 0 0
Colombia
State/province [64] 0 0
Valle Del Cauca
Country [65] 0 0
Costa Rica
State/province [65] 0 0
San Jose
Country [66] 0 0
France
State/province [66] 0 0
Calvados
Country [67] 0 0
France
State/province [67] 0 0
Cote-d Or
Country [68] 0 0
France
State/province [68] 0 0
Haute-Garonne
Country [69] 0 0
France
State/province [69] 0 0
Hauts-de-Seine
Country [70] 0 0
France
State/province [70] 0 0
Herault
Country [71] 0 0
France
State/province [71] 0 0
Moselle
Country [72] 0 0
France
State/province [72] 0 0
Nord-Pas-de-Calais
Country [73] 0 0
France
State/province [73] 0 0
Provence-Alpes-Cote-d Azur
Country [74] 0 0
France
State/province [74] 0 0
Puy-de-Dome
Country [75] 0 0
France
State/province [75] 0 0
Sarthe
Country [76] 0 0
France
State/province [76] 0 0
Val-de-Marne
Country [77] 0 0
France
State/province [77] 0 0
Paris
Country [78] 0 0
Germany
State/province [78] 0 0
Baden-Wurttemberg
Country [79] 0 0
Germany
State/province [79] 0 0
Bayern
Country [80] 0 0
Germany
State/province [80] 0 0
Hessen
Country [81] 0 0
Germany
State/province [81] 0 0
Niedersachsen
Country [82] 0 0
Germany
State/province [82] 0 0
Nordrhein-Westfalen
Country [83] 0 0
Germany
State/province [83] 0 0
Saarland
Country [84] 0 0
Germany
State/province [84] 0 0
Sachsen
Country [85] 0 0
Germany
State/province [85] 0 0
Thuringen
Country [86] 0 0
Hungary
State/province [86] 0 0
Bacs-Kiskun
Country [87] 0 0
Hungary
State/province [87] 0 0
Baranya
Country [88] 0 0
Hungary
State/province [88] 0 0
Borsod-Abauj-Zemplen
Country [89] 0 0
Hungary
State/province [89] 0 0
Budapest
Country [90] 0 0
Hungary
State/province [90] 0 0
Debrecen
Country [91] 0 0
Hungary
State/province [91] 0 0
Kaposvar
Country [92] 0 0
Ireland
State/province [92] 0 0
Cork
Country [93] 0 0
Ireland
State/province [93] 0 0
Dublin
Country [94] 0 0
Israel
State/province [94] 0 0
Afula
Country [95] 0 0
Israel
State/province [95] 0 0
Ashdod
Country [96] 0 0
Israel
State/province [96] 0 0
Beer Sheva
Country [97] 0 0
Israel
State/province [97] 0 0
Haifa
Country [98] 0 0
Israel
State/province [98] 0 0
Jerusalem
Country [99] 0 0
Israel
State/province [99] 0 0
Kfar-Saba
Country [100] 0 0
Israel
State/province [100] 0 0
Nazareth
Country [101] 0 0
Israel
State/province [101] 0 0
Petah Tikva
Country [102] 0 0
Israel
State/province [102] 0 0
Ramat Gan
Country [103] 0 0
Israel
State/province [103] 0 0
Rehovot
Country [104] 0 0
Israel
State/province [104] 0 0
Tel Aviv
Country [105] 0 0
Japan
State/province [105] 0 0
Aichi
Country [106] 0 0
Japan
State/province [106] 0 0
Chiba
Country [107] 0 0
Japan
State/province [107] 0 0
Hokkaido
Country [108] 0 0
Japan
State/province [108] 0 0
Hyogo
Country [109] 0 0
Japan
State/province [109] 0 0
Kanagawa
Country [110] 0 0
Japan
State/province [110] 0 0
Saitama
Country [111] 0 0
Japan
State/province [111] 0 0
Shizuoka
Country [112] 0 0
Japan
State/province [112] 0 0
Fukushima
Country [113] 0 0
Japan
State/province [113] 0 0
Hiroshima
Country [114] 0 0
Japan
State/province [114] 0 0
Kumamoto
Country [115] 0 0
Japan
State/province [115] 0 0
Osaka
Country [116] 0 0
Japan
State/province [116] 0 0
Tokyo
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Kyonggi-do
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Seoul
Country [119] 0 0
New Zealand
State/province [119] 0 0
Bay Of Plenty
Country [120] 0 0
New Zealand
State/province [120] 0 0
Canterbury
Country [121] 0 0
New Zealand
State/province [121] 0 0
Wellington
Country [122] 0 0
Poland
State/province [122] 0 0
Dolnoslaskie
Country [123] 0 0
Poland
State/province [123] 0 0
Kujawsko-pomorskie
Country [124] 0 0
Poland
State/province [124] 0 0
Lodzkie
Country [125] 0 0
Poland
State/province [125] 0 0
Mazowieckie
Country [126] 0 0
Poland
State/province [126] 0 0
Podlaskie
Country [127] 0 0
Poland
State/province [127] 0 0
Pomorskie
Country [128] 0 0
Poland
State/province [128] 0 0
Slaskie
Country [129] 0 0
Portugal
State/province [129] 0 0
Aveiro
Country [130] 0 0
Portugal
State/province [130] 0 0
Lisboa
Country [131] 0 0
Portugal
State/province [131] 0 0
Porto
Country [132] 0 0
Puerto Rico
State/province [132] 0 0
San Juan
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Arkhangel Skaya Oblast
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Baskortostan, Respublika
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Moskva
Country [136] 0 0
Russian Federation
State/province [136] 0 0
Ryazanskaya Oblast
Country [137] 0 0
Russian Federation
State/province [137] 0 0
Sankt-Peterburg
Country [138] 0 0
Russian Federation
State/province [138] 0 0
Tatarstan, Respublika
Country [139] 0 0
Russian Federation
State/province [139] 0 0
Tomskaya Oblast
Country [140] 0 0
Spain
State/province [140] 0 0
Barcelona
Country [141] 0 0
Spain
State/province [141] 0 0
La Coruna
Country [142] 0 0
Spain
State/province [142] 0 0
Madrid, Comunidad De
Country [143] 0 0
Spain
State/province [143] 0 0
Madrid
Country [144] 0 0
Spain
State/province [144] 0 0
Valenciana, Comunitat
Country [145] 0 0
Spain
State/province [145] 0 0
Jaen
Country [146] 0 0
Spain
State/province [146] 0 0
Sevilla
Country [147] 0 0
Spain
State/province [147] 0 0
Valencia
Country [148] 0 0
Taiwan
State/province [148] 0 0
Taichung
Country [149] 0 0
Taiwan
State/province [149] 0 0
Tainan
Country [150] 0 0
Taiwan
State/province [150] 0 0
Taipei
Country [151] 0 0
Taiwan
State/province [151] 0 0
Taoyuan
Country [152] 0 0
Ukraine
State/province [152] 0 0
Dnipropetrovska Oblast
Country [153] 0 0
Ukraine
State/province [153] 0 0
Ivano-Frankivska Oblast
Country [154] 0 0
Ukraine
State/province [154] 0 0
Kharkivska Oblast
Country [155] 0 0
Ukraine
State/province [155] 0 0
Khersonska Oblast
Country [156] 0 0
Ukraine
State/province [156] 0 0
Khmelnytska Oblast
Country [157] 0 0
Ukraine
State/province [157] 0 0
Kyivska Oblast
Country [158] 0 0
Ukraine
State/province [158] 0 0
Odeska Oblast
Country [159] 0 0
Ukraine
State/province [159] 0 0
Zaporizka Oblast
Country [160] 0 0
Ukraine
State/province [160] 0 0
Kyiv
Country [161] 0 0
United Kingdom
State/province [161] 0 0
Bristol, City Of
Country [162] 0 0
United Kingdom
State/province [162] 0 0
England
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Essex
Country [164] 0 0
United Kingdom
State/province [164] 0 0
London, City Of
Country [165] 0 0
United Kingdom
State/province [165] 0 0
Solihull
Country [166] 0 0
United Kingdom
State/province [166] 0 0
Truro

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475)
versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant
(post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage
estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-)
breast cancer.

The primary study hypotheses are: 1) pembrolizumab is superior to placebo, both in
combination with the protocol-specified neoadjuvant anticancer therapy, as assessed by
pathological Complete Response (pCR) rate defined by the local pathologist, and 2)
pembrolizumab is superior to placebo (both in combination with the protocol-specified
neoadjuvant and adjuvant anticancer therapies) as assessed by Event-Free Survival (EFS) as
determined by the investigator. The study is considered to have met its primary objective if
pembrolizumab is superior to placebo with respect to either pCR (ypT0/Tis ypN0) or EFS.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03725059
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/ct2/show/NCT03725059